{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:54:57Z","timestamp":1770994497063,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1693,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1111\/j.1440-0960.2010.00717.x","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T04:00:37Z","timestamp":1294891237000},"page":"19-26","source":"Crossref","is-referenced-by-count":15,"title":["Enfuvirtide injection site reactions: A clinical and histopathological appraisal"],"prefix":"10.1111","volume":"52","author":[{"given":"Brian J","family":"Wallace","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"King-Bing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah L","family":"Pett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kossard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot J","family":"Whitfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,1,12]]},"reference":[{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1473-3099(04)01058-8","article-title":"Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development","volume":"4","author":"Cooper","year":"2004","journal-title":"Lancet Infect. Dis."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drug resistant HIV-1 in Europe and Australia","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1386-6532(03)00116-1","article-title":"Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1 infected patients","volume":"28","author":"Lalezari","year":"2003","journal-title":"J. Clin. Virol."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB4|cit4","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf"},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB5|cit5","unstructured":"Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events http:\/\/www.ucdmc.ucdavis.edu\/clinicaltrials\/documents\/DAIDS_AE_GradingTable_FinalDec2004.pdf"},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection","volume":"359","author":"Cooper","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3851\/IMP1301","article-title":"Efficacy and safety of darunavir\/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96","volume":"14","author":"Arasteh","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/135965350801300304","article-title":"A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study)","volume":"13","author":"Boyd","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJMoa0903175","article-title":"Interleukin-2 therapy in patients with HIV infection","volume":"361","author":"Abrams","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0190-9622(03)02099-1","article-title":"Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide","volume":"49","author":"Ball","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jac\/dkh141","article-title":"Cutaneous injection site reactions to long-term therapy with enfuvirtide","volume":"53","author":"Maggi","year":"2004","journal-title":"J. Antimicrob. Chemoth."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-151-7-200910060-00017","article-title":"Localized amyloidosis at the site of enfuvirtide injection","volume":"151","author":"Morilla","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1034\/j.1600-0560.2002.290105.x","article-title":"A light microscopic and immunohistochemical evaluation of scars","volume":"29","author":"Kamath","year":"2002","journal-title":"J. Cutan. Pathol."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1600-0560.2009.01201.x","article-title":"Elastic fiber pattern in scleroderma\/morphea","volume":"36","author":"Walters","year":"2009","journal-title":"J. Cutan. Pathol."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archderm.1955.01540270050005","article-title":"Elastic fibers in unusual dermatoses","volume":"71","author":"Winer","year":"1955","journal-title":"Arch. Dermatol."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB16|cit16","first-page":"815","volume-title":"Pathology of the Skin with Clinical Correlations","author":"McKee","year":"2005"},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00000372-199510000-00007","article-title":"Decreased expression of the human progenitor cell antigen (CD34) in morphea","volume":"17","author":"Skobieranda","year":"1995","journal-title":"Am. J. Dermatopathol."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB18|cit18","first-page":"274","article-title":"Factor XIII of blood coagulation modulates collagen biosynthesis by fibroblasts in vitro","volume":"19","author":"Paye","year":"1989","journal-title":"Haemostasis"},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/00000478-199312000-00001","article-title":"Atypical fibroxanthoma. Multiple immunohistologic profiles","volume":"17","author":"Longacre","year":"1993","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2133.1989.tb15509.x","article-title":"Characterisation of Factor XIIIa positive dermal dendritic cells in normal and inflamed skin","volume":"121","author":"Cerio","year":"1989","journal-title":"Br. J. Dermatol."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/jsre.1995.1179","article-title":"Immunolocalization of FXIIIa+ dendritic cells in human burn wounds","volume":"59","author":"Gibran","year":"1995","journal-title":"J. Surg. Res."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1440-1827.2007.02105.x","article-title":"Factor XIIIa-positive dermal dendritic cells in keloids and hypertrophic and mature scars","volume":"57","author":"Onodera","year":"2007","journal-title":"Pathol. Int."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1046\/j.1365-2133.2000.03886.x","article-title":"Analysis of dendritic cell populations using a revised histological staging of morphoea","volume":"143","author":"Gilmour","year":"2000","journal-title":"Br. J. Dermatol."},{"issue":"62","key":"10.1111\/j.1440-0960.2010.00717.x-BIB24|cit24","first-page":"75","article-title":"Analysis of dendritic cell populations in lichen sclerosis","volume":"147","author":"Rozario","year":"2002","journal-title":"Br. J. Dermatol."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/01.aids.0000131375.21070.06","article-title":"Immune restoration disease after antiretroviral therapy","volume":"18","author":"French","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/135965350601100406","article-title":"Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study","volume":"11","author":"Dwyer","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0738-081X(98)00006-6","article-title":"Drug-Induced Scleroderma and Sclerodermiform Conditions","volume":"16","author":"Haustein","year":"1998","journal-title":"Clin. Dermatol."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"11126","DOI":"10.1074\/jbc.M800200200","article-title":"Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor","volume":"283","author":"He","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/652190","article-title":"Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody","volume":"201","author":"Jacobson","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1111\/j.1440-0960.2010.00717.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/QAI.0b013e3181cbdaff","article-title":"Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension","volume":"53","author":"Falutz","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-0960.2010.00717.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1440-0960.2010.00717.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T20:49:28Z","timestamp":1685911768000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-0960.2010.00717.x"}},"subtitle":["Enfuvirtide injection site reactions"],"short-title":[],"issued":{"date-parts":[[2011,1,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1440-0960.2010.00717.x","relation":{},"ISSN":["0004-8380"],"issn-type":[{"value":"0004-8380","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1,12]]}}}